[{"address1": "1400 Sierra Point Parkway", "address2": "Building C Suite 200", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "650 822 5500", "fax": "650 636 9773", "website": "https://www.annexonbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barr\u00e9 syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.", "fullTimeEmployees": 70, "companyOfficers": [{"maxAge": 1, "name": "Mr. Douglas  Love Esq., J.D.", "age": 55, "title": "CEO, President & Director", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 980122, "exercisedValue": 0, "unexercisedValue": 516039}, {"maxAge": 1, "name": "Dr. Dean R. Artis Ph.D.", "age": 62, "title": "Chief Scientific Officer & Executive VP", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 797380, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ted  Yednock Ph.D.", "age": 65, "title": "Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 697760, "exercisedValue": 0, "unexercisedValue": 119297}, {"maxAge": 1, "name": "Ms. Jennifer  Lew", "age": 50, "title": "Executive VP, CFO & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 624195, "exercisedValue": 0, "unexercisedValue": 13124}, {"maxAge": 1, "name": "Mr. Michael  Overdorf M.B.A.", "age": 52, "title": "Executive VP & Chief Business Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 580469, "exercisedValue": 0, "unexercisedValue": 13124}, {"maxAge": 1, "name": "Mr. Henk-Andre  Kroon M.D.", "title": "Senior Vice President of Translational Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jamie  Dananberg M.D.", "age": 65, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1719619200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.82, "open": 4.83, "dayLow": 4.675, "dayHigh": 4.98, "regularMarketPreviousClose": 4.82, "regularMarketOpen": 4.83, "regularMarketDayLow": 4.675, "regularMarketDayHigh": 4.98, "beta": 1.297, "forwardPE": -4.666667, "volume": 5289932, "regularMarketVolume": 5289932, "averageVolume": 2879387, "averageVolume10days": 2380490, "averageDailyVolume10Day": 2380490, "bid": 4.88, "ask": 4.91, "bidSize": 400, "askSize": 800, "marketCap": 516528608, "fiftyTwoWeekLow": 1.57, "fiftyTwoWeekHigh": 8.4, "fiftyDayAverage": 4.9563, "twoHundredDayAverage": 4.1495, "currency": "USD", "enterpriseValue": 218660048, "floatShares": 67044610, "sharesOutstanding": 105414000, "sharesShort": 4053215, "sharesShortPriorMonth": 7569377, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0385, "heldPercentInsiders": 0.0039500003, "heldPercentInstitutions": 0.95533997, "shortRatio": 0.87, "shortPercentOfFloat": 0.0461, "impliedSharesOutstanding": 105414000, "bookValue": 2.9, "priceToBook": 1.6896552, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -120737000, "trailingEps": -1.46, "forwardEps": -1.05, "pegRatio": -0.13, "enterpriseToEbitda": -1.696, "52WeekChange": 0.42028987, "SandP52WeekChange": 0.22553468, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ANNX", "underlyingSymbol": "ANNX", "shortName": "Annexon, Inc.", "longName": "Annexon, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "39e86d0b-392a-371c-9e14-996bb9ee6158", "messageBoardId": "finmb_279883519", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.9, "targetHighPrice": 30.0, "targetLowPrice": 10.0, "targetMeanPrice": 16.4, "targetMedianPrice": 14.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 264948000, "totalCashPerShare": 2.867, "ebitda": -128903000, "totalDebt": 30785000, "quickRatio": 20.174, "currentRatio": 20.615, "debtToEquity": 11.732, "returnOnAssets": -0.28597, "returnOnEquity": -0.50595003, "freeCashflow": -73527128, "operatingCashflow": -116416000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-30"}]